An open-label single-arm pilot phase II study (PX-171-003-A0) of low-dose, single-agent carfilzomib in patients with relapsed and refractory multiple myeloma.
about
Salvage therapies in relapsed and/or refractory myeloma: what is current and what is the future?Carfilzomib/pomalidomide single-agent or in combination with other agents for the management of relapsed/refractory multiple myeloma : a meta-analysis of 37 trialsFirst line vs delayed transplantation in myeloma: Certainties and controversiesEvolving paradigms in the treatment of relapsed/refractory multiple myeloma: increased options and increased complexityCurrent and emerging treatment options for patients with relapsed myelomaFrom epoxomicin to carfilzomib: chemistry, biology, and medical outcomesTargeted treatments for multiple myeloma: specific role of carfilzomibNew drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG)Incidence and management of adverse events in patients with relapsed and/or refractory multiple myeloma receiving single-agent carfilzomibA clinical update on the role of carfilzomib in the treatment of relapsed or refractory multiple myelomaTrial Watch: Proteasomal inhibitors for anticancer therapyCarfilzomib and pomalidomide in patients with relapsed and/or refractory multiple myeloma with baseline risk factorsCarfilzomib: a second-generation proteasome inhibitor for the treatment of relapsed and refractory multiple myeloma.Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma.Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies.Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma.A phase 2 single-center study of carfilzomib 56 mg/m2 with or without low-dose dexamethasone in relapsed multiple myeloma.A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS).Update on the optimal use of bortezomib in the treatment of multiple myelomaImpact of breast cancer stage, time from diagnosis and chemotherapy on plasma and cellular biomarkers of hypercoagulability.The MUK five protocol: a phase II randomised, controlled, parallel group, multi-centre trial of carfilzomib, cyclophosphamide and dexamethasone (CCD) vs. cyclophosphamide, bortezomib (Velcade) and dexamethasone (CVD) for first relapse and primary reSpecificity of Protein Covalent Modification by the Electrophilic Proteasome Inhibitor Carfilzomib in Human CellsPolymer micelle formulations of proteasome inhibitor carfilzomib for improved metabolic stability and anticancer efficacy in human multiple myeloma and lung cancer cell linesCarfilzomib and the cardiorenal system in myeloma: an endothelial effect?David and Goliath: chemical perturbation of eukaryotes by bacteria.A Tumor Growth Inhibition Model Based on M-Protein Levels in Subjects With Relapsed/Refractory Multiple Myeloma Following Single-Agent Carfilzomib UseA phase 1/2 study of carfilzomib in Japanese patients with relapsed and/or refractory multiple myelomaA phase I/II study of carfilzomib 2-10-min infusion in patients with advanced solid tumors.Posttransplant maintenance therapy in multiple myeloma: the changing landscape.Carfilzomib: a novel agent for multiple myeloma.Choosing treatment options for patients with relapsed/refractory multiple myeloma.Future agents and treatment directions in multiple myeloma.Current Phase II investigational proteasome inhibitors for the treatment of multiple myeloma.Salvage therapy of multiple myeloma: the new generation drugs.Chemotherapy-induced peripheral neurotoxicity (CIPN): what we need and what we know.Carfilzomib and pomalidomide: recent advances in the treatment of multiple myeloma.Advances in targeted therapy for the treatment of patients with relapsed/refractory multiple myeloma.Tumor lysis syndrome in the era of novel and targeted agents in patients with hematologic malignancies: a systematic review.Carfilzomib Inhibits Constitutive NF-κB Activation in Mantle Cell Lymphoma B Cells and Leads to the Induction of Apoptosis.Targeting plasma cells: are we any closer to a panacea for diseases of antibody-secreting cells?
P2860
Q26740359-F6CC624B-48D8-44B2-9BAE-0FA25B15BB47Q26741620-35D0497A-4E0C-4D6C-9674-1EF8F88169DFQ26745957-B0FB62D8-83BC-438C-ABB3-290336CC1C6BQ26771331-C1D961D6-6330-4838-AB8A-E231A4BD06A1Q26830878-82DAD481-2FE2-496B-A3C6-E7A14FF8DFB6Q26864557-0D0BDF5E-3F74-4543-B90C-B3CA9F345B62Q26996524-00023BA7-489A-4000-8E02-F58D152B1480Q27004421-E88B08BD-8409-45DE-886D-D7FEAB84D7DBQ27014143-260C23BE-56BA-48E0-9544-6E0BF77213F6Q28067148-1CFE1707-7437-494B-BCCC-65CD434E68A4Q28082910-CF85B636-F519-4558-A9CD-60AD398BFFBBQ28084683-D18AADA3-3618-476D-9E5F-B3A35E1373B7Q33405181-86622879-B1FE-40D5-8FEE-EEAB290FC97CQ33406135-D2812385-71B6-43B2-B921-EDA9E2C9C996Q33409681-7A8385B3-A3DC-42B0-8D07-0664210D022CQ33410213-9FAC1A4E-5D28-4B8F-93E4-22B85D8909CCQ33416105-4C5A62AF-48BB-469C-B98A-F4C62166D1E0Q33433893-72334585-8BF3-4FBF-BA42-5BB063B9445DQ33440007-92F16707-9FB1-48A3-8941-15FCE89D7738Q34893956-C99291B7-02A0-4640-8E93-57CAB700D436Q36020680-CF79AE47-750A-480D-9A78-CFF1871404E9Q36098363-0A1B1C43-AC30-4C31-8AB6-729476CF22AAQ36186214-43118B99-DB07-459D-9811-A2954EDFDB9FQ36548064-40FDCC1C-D2A1-4D19-A057-8102CCE0C18CQ36577080-A61F0275-AEED-4C57-B139-4C5674C888BCQ36595921-A3DE102A-284F-4E29-B308-2ACDE7339A35Q36671445-7B1BF0AF-073D-4425-967C-2F4A8C0A4AABQ37199819-B572DC56-CBF8-4139-B33E-8883C02C004AQ37737800-036DFE80-DEFE-4C90-9C49-A4625961D53FQ38120296-4048AD37-650C-406C-993B-D2FDEF7D73AFQ38170453-938E0562-47FD-4338-AE66-0C72A6C9BA48Q38172300-6C099C09-CB1E-4DBD-BC20-FAFE189166E1Q38218209-649B4B82-D938-447F-A6B6-FB83BEBD8060Q38223433-0779B757-98D8-4EB2-BF9A-2EAC00DE2A92Q38224422-6AC6E2B8-E4C4-43B7-A440-A35C227DAD4AQ38231991-A5D43668-F413-4DF7-90C2-BC30D7E41300Q38630472-52763C0B-463D-4822-8EB8-45AAB5ED1AE2Q38693748-149E517D-8982-40FC-830C-3ADDAA9328E4Q38716176-DD49CEC6-0AF1-43B8-BC72-61217FC04B8EQ38728585-5A8A1222-7AEE-4D63-8686-2674F973E8F3
P2860
An open-label single-arm pilot phase II study (PX-171-003-A0) of low-dose, single-agent carfilzomib in patients with relapsed and refractory multiple myeloma.
description
2012 nî lūn-bûn
@nan
2012 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
An open-label single-arm pilot ...... d refractory multiple myeloma.
@ast
An open-label single-arm pilot ...... d refractory multiple myeloma.
@en
type
label
An open-label single-arm pilot ...... d refractory multiple myeloma.
@ast
An open-label single-arm pilot ...... d refractory multiple myeloma.
@en
prefLabel
An open-label single-arm pilot ...... d refractory multiple myeloma.
@ast
An open-label single-arm pilot ...... d refractory multiple myeloma.
@en
P2093
P50
P1476
An open-label single-arm pilot ...... d refractory multiple myeloma.
@en
P2093
A Keith Stewart
Alvin Wong
Andrzej J Jakubowiak
David S Siegel
George Somlo
Lori A Kunkel
Nizar Bahlis
Sundar Jagannath
Tony Reiman
P304
P356
10.1016/J.CLML.2012.08.003
P407
P577
2012-10-01T00:00:00Z